scholarly journals Yifei Sanjie Formula Treats Chronic Obstructive Pulmonary Disease by Regulating Lung Microbiota Dysbiosis

2021 ◽  
Author(s):  
Yue-Ying Wu ◽  
Bo Qiao ◽  
Qiang Zhang ◽  
Wen-Qing Jia ◽  
Hui Meng ◽  
...  
Keyword(s):  
Pulmonary Disease ◽  
Rat Model ◽  
Bacterial Flora ◽  
Pulmonary Diseases ◽  
Chronic Obstructive ◽  
Ventilatory Function ◽  
Obstructive Pulmonary Disease ◽  
Caspase 1 ◽  
Inflammation Cytokines

Abstract BackgroundChronic obstructive pulmonary disease (COPD) is one of the most common pulmonary diseases. There is evidence to suggest that dysbiosis of pulmonary microbiota participates in COPD development. Yifei Sanjie Formula (YS) is widely used to treat diseases in respiratory systems, yet its mechanisms are little known. MethodsIn the present study, the efficacy of YS was evaluated by analyzing its effects on the severity of pulmonary pathological damage, pulmonary function, pro-inflammation cytokines, the activation of NLRP3/caspase-1/IL-1β signaling pathway, and changes of lung microbiota. ResultsYS improved animal behaviors, prevented declines in pulmonary ventilatory function and lung injury in a rat model of COPD. Administration of YS significantly suppressed the release of proinflammatory cytokines and collagen deposition and downregulated NLRP3/caspase-1/IL-1β signaling in vivo. YS changed the relative abundance of specific pulmonary microbiota and modulated bacterial flora in the rat model. ConclusionsThese results suggest that the effects of YS involved lung microbes and anti-inflammatory mechanisms.

scholarly journals Asthma and COPD Patients’ Perception of Appropriate Metered-Dose Inhaler Technique

Dose-Response ◽  
2020 ◽  
Vol 18 (2) ◽  
pp. 155932582091783 ◽  
Author(s):  
Wijdan H. Ramadan ◽  
Aline Sarkis ◽  
Sandrine Sarine Aderian ◽  
Aline Milane
Keyword(s):  
Pulmonary Disease ◽  
Reliability And Validity ◽  
Pulmonary Diseases ◽  
Dose Inhaler ◽  
Chronic Obstructive ◽  
Community Pharmacies ◽  
Obstructive Pulmonary Disease ◽  
Survey Tool ◽  
Metered Dose ◽  
The Mean

Objectives: Asthma and chronic obstructive pulmonary disease (COPD) are chronic illnesses of the airways affecting a good number of people in Lebanon and the Middle East. Pressurized metered-dose inhalers (pMDIs) are important drug delivery systems used to treat such pulmonary diseases. Drugs proven to be valuable and effective may fail to act effectively if such inhalers are used incorrectly. The purpose of this study was to assess the technical use of pMDIs by patients with pulmonary diseases presenting to the community pharmacies in Lebanon. Methods: A structured questionnaire was developed to collect data. A total of 601 patients using drugs delivered through pMDIs and presenting to 12 Lebanese community pharmacies were recruited to participate in the research project. The questionnaire items were divided into 3 subscales: subscale 1—assessing the device preparation; subscale 2—investigating the device use; and subscale 3—examining the knowledge and use of spacers. After confirming the reliability and validity of the survey tool, patients’ responses were analyzed and compared according to many variables. Results: Many patients answered inaccurately to questions assessing both the device preparation and use. Around 40% of patients said they do not coordinate the inhalation with pressing the canister down. The mean scores were 1.72 (± 0.73) over 6 and 5.67 (± 1.44) over 7 for subscales 1 and 2, respectively. The mean total score on all questions was 7.39 over 13, with a standard deviation of 1.75. While patients’ age did not impact the results, asthmatic, well-educated, male patients had fewer wrong answers when it comes to preparing and using the device ( P < .01). Conclusions: Our study showed that many patients with asthma and COPD might not be properly using their pMDIs. Appropriate inhaler use is crucial for successful pulmonary disease management. As pMDIs are one of the most difficult devices to use, proper and tailored instructions should be given to patients.

In Vivo Thrombin Generation and Platelet Hyperactivity in Patients with Chronic Obstructive Pulmonary Disease

Platelets ◽  
1994 ◽  
Vol 5 (5) ◽  
pp. 276-278 ◽  
Author(s):  
P. Ferroni ◽  
S. Basili ◽  
F. M. Pulcinelli ◽  
G. Pettirossi ◽  
C. Alessandri ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Thrombin Generation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

scholarly journals Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate Airway Inflammation in a Rat Model of chronic obstructive pulmonary disease (COPD)

2020 ◽  
Author(s):  
Noridzzaida Ridzuan ◽  
Norashikin Zakaria ◽  
Darius Widera ◽  
Jonathan Sheard ◽  
Mitsuru Morimoto ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Pulmonary Disease ◽  
Umbilical Cord ◽  
Extracellular Vesicles ◽  
Rat Model ◽  
Chronic Obstructive ◽  
Human Umbilical Cord ◽  
Obstructive Pulmonary Disease

Abstract Background: Chronic obstructive pulmonary disease (COPD) is an incurable and debilitating chronic disease characterized by progressive airflow limitation associated with abnormal levels of tissue inflammation. Therefore, stem cell-based approaches to tackle the condition are currently a focus of regenerative therapies for COPD. Extracellular vesicles (EVs) released by all cell types are crucially involved in paracrine, extracellular communication. Recent advances in the field suggest that stem cell-derived EVs possess a therapeutic potential which is comparable to the cells of their origin.Methods: In this study, we assessed the potential anti-inflammatory effects of human umbilical cord mesenchymal stem cell (hUC-MSCs) derived EVs in a rat model of COPD. EVs were isolated from hUC-MSCs and characterized by the transmission electron microscope, western blotting, and nanoparticle tracking analysis. As a model of COPD, male Sprague Dawley rats were exposed to cigarette smoke for up to 12 weeks, followed by transplantation of hUC-MSCs or application of hUC-MSCs-derived EVs. Lung tissue was subjected to histological analysis using hematoxylin and eosin staining, alcian blue-periodic acid Schiff (AB-PAS) staining, and immunofluorescence staining. Gene expression in the lung tissue was assessed using microarray analysis. Statistical analyses were performed using GraphPad Prism 7 version 7.0 (GraphPad Software, USA). Student’s t-test was used to compare between 2 groups. Comparison among more than 2 groups was done using one-way analysis of variance (ANOVA). Data presented as median±standard deviation (SD).Results: Both, transplantation of hUC-MSCs and application of EVs resulted in a reduction of peribronchial and perivascular inflammation, alveolar septal thickening associated with mononuclear inflammation, as well as a decreased number of goblet cells. Moreover, hUC-MSCs and EVs ameliorated the loss of alveolar septa in the emphysematous lung of COPD rats and reduced the levels of NF-κB subunit p65 in the tissue. Subsequent microarray analysis revealed that both hUC-MSCs and EVs significantly regulate multiple pathways known to be associated with COPD. Conclusions: In conclusion, we show that hUC-MSCs-derived EVs effectively ameliorate by COPD-induced inflammation. Thus, EVs could serve as a new cell-free based therapy for the treatment of COPD.

scholarly journals Urinary protein changes in the early phase of smoking-induced Chronic Obstructive Pulmonary Disease in a rat model

2018 ◽  
Author(s):  
He Huang ◽  
Ting Wang ◽  
Youhe Gao
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Rat Model ◽  
Chronic Obstructive ◽  
Pathological Changes ◽  
Obstructive Pulmonary Disease ◽  
Human Orthologs ◽  
Proteomics Technology ◽  
Differential Proteins

AbstractChronic obstructive pulmonary disease (COPD) is a group of severe respiratory diseases. Identifying COPD through early urinary biomarkers by proteomics technology may help to reduce the mortality rate of the disease, improve the quality of life of patients and reduce the burden on society. Urine samples from a COPD rat model induced by smoking were taken at week 2, week 4 and week 8. By LC-MS/MS, 15 differential proteins with human orthologs were identified. After smoking for 2 weeks when there were no significant pathological changes, 8 differential proteins were identified: 2 proteins had been reported to be markers of COPD, while 4 proteins were associated with COPD. After smoking for 4 weeks, which is when slight pathological changes were observed, 7 differential proteins were identified: 3 of them were reported to be associated with COPD, while 1 protein had been reported to be a marker of COPD. After smoking for 8 weeks, there were significant pathological changes: 5 differential proteins were identified, 3 of which were reported to be associated with COPD. The results of this study suggest that differential urinary proteins may provide important clues for the early diagnosis of COPD.

scholarly journals Magnesium serum and urine concentration in patients with acute and chronic pulmonary disease

2004 ◽  
Vol 23 (2) ◽  
pp. 155-160 ◽  
Author(s):  
Ljudmila Nagorni-Obradovic ◽  
Svetlana Ignjatovic ◽  
Vesna Petrovic ◽  
Marija Mitic-Milikic
Keyword(s):  
Pulmonary Disease ◽  
Urine Concentration ◽  
Pulmonary Diseases ◽  
Magnesium Concentration ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
End Of Treatment ◽  
Chronic Pulmonary Diseases ◽  
Serum And Urine

In this study we determined magnesium concentration in serum and in 24-hour urine, at the start (To) and at the end of treatment (T1), in 56 patients with acute pulmonary disease (B1) and in 58 patients with chronic obstructive pulmonary disease - COPD (B2). In group B1 there was disbalance of Mg in serum in 14-25% patients at the start of treatment (To) which decreased significantly at the end of treatment (T1) and persisted in 4-7.1% patients (p < 0.05). In group B2 distribution of normal, decreased and increased values of Mg in serum was similar in patients in period To and T1 (p > 0.05). In group B1, 9 (16.1%) patients had hypomagnesemia at the start of treatment (To), which was accompanied by increased concentration of Mg in 24-hour urine of only 4 (7.2%) patients. There is a possibility that there was extrarenal elimination of Mg in patients with acute pulmonary disease or there was some kind of transcellular distribution. In group B2 in period To, there was proportional ratio between hypomagnesemia (12-20.7% patients) and increased concentration of Mg in 24-hour urine (20 -34.5% patients). This could be because of renal loss. Simultaneous determination and follow up of magnesium in serum and in 24-hour urine can give us reliable information about homeostasis of this electrolyte in acute and chronic pulmonary diseases.

Sign in / Sign up

Export Citation Format

Share Document